Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.

@article{Rosa2016RoleOA,
  title={Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension: One-Year Outcomes of Randomized PRAGUE-15 Study.},
  author={J{\'a}n Rosa and Petr Widimsk{\'y} and Petr Waldauf and Luk{\'a}s Lambert and Tomas Zelinka and Milo{\vs} T{\'a}borsk{\'y} and Marian Branny and Petr Tou{\vs}ek and Ondřej Petr{\'a}k and K Curila and Frantisek Bednar and Robert Holaj and Branislav {\vS}trauch and Jan V{\'a}clav{\'i}k and Igor Nykl and Zuzana Kr{\'a}tk{\'a} and Eva Koci{\'a}nov{\'a} and Otakar Jiravsk{\'y} and Gabriela Rappov{\'a} and Tom{\'a}{\vs} Indra and Jiř{\'i} Widimsk{\'y}},
  journal={Hypertension},
  year={2016},
  volume={67 2},
  pages={397-403}
}
This randomized, multicenter study compared the relative efficacy of renal denervation (RDN) versus pharmacotherapy alone in patients with true resistant hypertension and assessed the effect of spironolactone addition. We present here the 12-month data. A total of 106 patients with true resistant hypertension were enrolled in this study: 52 patients were randomized to RDN and 54 patients to the spironolactone addition, with baseline systolic blood pressure of 159±17 and 155±17 mm Hg and average… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
13 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…